Figure 1
Delivery of Hp91 in nanoparticles to BM-DCs increases HER2-specific CTL responses in vitro. Immature mouse BM-DCs (105) were exposed to media, 55 μg/ml of free Hp91 peptide or the same amount delivered inside PLGA-NPs, or lipopolysaccharide (LPS; 10 ng/mL). After 2 days the cells were collected, washed, and pulsed with HER2 peptide (100 ng/mL) for 1 h prior to the overnight co-culture with the HER-2/neu-specific CTL line in an ELISPOT assay. The number of IFN-γ spot-forming cells is shown as means (± standard error of the mean (SEM)) of two independent experiments. **Indicates statistical significance P <0.005. BM-DCs, bone marrow-derived dendritic cells; CTL, cytotoxic T lymphocyte; ELISPOT, enzyme-linked immunospot; HER2, human epidermal growth factor receptor 2; IFN-γ, interferon gamma; PLGA-NPs, poly(D,L-lactic-co-glycolic) acid nanoparticles.